Product Pipeline

 

Mercia has a robust pipeline of products under development.  A number of our lead candidates are in or about to enter clinical development, with others in late stage lead candidate selection or preclinical evaluation.

Mercia has identified a number of disease-specific antigens for which it plans to develop future pipeline candidates addressing the autoaggressive/regulatory imbalance of the immune system in autoimmune disease and others that play key roles in serious chronic diseases that are amenable to targeted disease-specific immunotherapy.